Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$2.64 -1.1%	$2.95	$2.56 ▼ $5.64	$23.63M	1.2	37,294 shs	40,726 shs
RNAZ TransCode Therapeutics	$7.66 -1.7%	$8.53	$6.15 ▼ $987.02	$6.49M	1.32	103,337 shs	7,830 shs
SNYR Synergy CHC	$2.55 +1.2%	$2.07	$0.36 ▼ $10.00	$23.17M	N/A	87,840 shs	32,218 shs
TPST Tempest Therapeutics	$7.15 +1.6%	$7.00	$5.35 ▼ $30.03	$25.92M	-2	166,367 shs	172,201 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	-1.12%	-9.59%	-8.97%	-8.65%	-49.14%
RNAZ TransCode Therapeutics	-1.67%	+9.74%	+9.90%	-47.39%	-99.98%
SNYR Synergy CHC	+1.19%	+15.38%	+30.10%	-20.56%	+25,400.00%
TPST Tempest Therapeutics	+1.56%	+3.62%	+14.77%	-34.52%	-73.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Dare Bioscience	1.1962 of 5 stars	3.3	3.0	0.6	0.0	0.0
RNAZ TransCode Therapeutics	1.5163 of 5 stars	3.5	3.0	0.0	0.0	0.6
SNYR Synergy CHC	3.7964 of 5 stars	3.8	0.0	2.6	3.3	1.9
TPST Tempest Therapeutics	2.0504 of 5 stars	3.3	5.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	354.55% Upside
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	3,555.35% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	292.16% Upside
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	319.58% Upside

Current Analyst Ratings Breakdown

Latest RNAZ, TPST, DARE, and SNYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	RNAZ TransCode Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$560.00 ➝ $280.00
4/10/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$16.00 ➝ $16.00
4/10/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Perform	$7.00 ➝ $9.00
4/1/2025	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/28/2025	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$169.00 ➝ $91.00
3/28/2025	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$611.00 ➝ $208.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Dare Bioscience	$10K	2,336.40	N/A	N/A	($0.69) per share	-3.83
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	($54.96) per share	N/A
SNYR Synergy CHC	$34.83M	0.67	$0.27 per share	9.47	($1.91) per share	-1.34
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$5.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-8.14%	8/11/2025 (Estimated)
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-578.88%	-222.61%	N/A
SNYR Synergy CHC	$2.12M	N/A	0.00	4.32	N/A	N/A	-8.48%	12.75%	N/A
TPST Tempest Therapeutics	-$41.84M	-$17.98	N/A	N/A	N/A	N/A	-305.51%	-119.74%	8/6/2025 (Estimated)

Latest RNAZ, TPST, DARE, and SNYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q4 2024	RNAZ TransCode Therapeutics	-$2.00	-$0.60	+$1.40	-$2.51	$0.30 million	N/A
5/15/2025	Q1 2025	SNYR Synergy CHC	$0.07	$0.10	+$0.03	$0.10	$9.03 million	$8.17 million
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/13/2025	Q1 2025	TPST Tempest Therapeutics	-$3.71	-$3.16	+$0.55	-$3.16	N/A	N/A
3/31/2025	Q4 2024	DARE Dare Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/31/2025	Q4 2024	SNYR Synergy CHC	$0.10	$0.01	-$0.09	$0.01	$10.55 million	$10.30 million
3/27/2025	Q4 2024	TPST Tempest Therapeutics	-$3.12	-$4.03	-$0.91	-$0.31	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Dare Bioscience	N/A	0.56	0.56
RNAZ TransCode Therapeutics	N/A	5.20	5.20
SNYR Synergy CHC	N/A	1.91	1.62
TPST Tempest Therapeutics	N/A	1.70	1.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Dare Bioscience	6.70%
RNAZ TransCode Therapeutics	N/A
SNYR Synergy CHC	N/A
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
DARE Dare Bioscience	4.00%
RNAZ TransCode Therapeutics	0.10%
SNYR Synergy CHC	56.60%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
RNAZ TransCode Therapeutics	9	830,000	832,000	Not Optionable
SNYR Synergy CHC	40	9.19 million	3.99 million	N/A
TPST Tempest Therapeutics	20	3.68 million	3.51 million	Optionable

RNAZ, TPST, DARE, and SNYR Headlines

Recent News About These Companies

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11, 2025 | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | quiverquant.comQ

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 28, 2025 | globenewswire.com

Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

April 25, 2025 | empr.comE

Cash-strapped Bay Area biotech company lays off all but 5 employees

April 24, 2025 | msn.com

Tempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495

April 23, 2025 | nasdaq.com

Tempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous Polyposis

April 23, 2025 | nasdaq.com

Tempest Therapeutics

April 22, 2025 | thepharmaletter.comT

Tempest Therapeutics stock rises on FDA Orphan Drug Designation

April 21, 2025 | in.investing.com

Tempest lays off 80% of workforce to ride out cash crunch

April 21, 2025 | fiercebiotech.comF

Tempest Therapeutics announces FDA granted ODD to TPST-1495

April 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, TPST, DARE, and SNYR Company Descriptions

Dare Bioscience NASDAQ:DARE

$2.64 -0.04 (-1.31%)

As of 06/25/2025 04:00 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

TransCode Therapeutics NASDAQ:RNAZ

$7.66 -0.13 (-1.67%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$7.83 +0.17 (+2.22%)

As of 06/25/2025 07:23 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Synergy CHC NASDAQ:SNYR

$2.55 +0.03 (+1.19%)

As of 06/25/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

Tempest Therapeutics NASDAQ:TPST

$7.15 +0.11 (+1.56%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$7.20 +0.05 (+0.69%)

As of 06/25/2025 07:58 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time